Abiraterone Acetate news

All news on Abiraterone Acetate (also known as Zytiga): plants, production capacities, investments and involved companies.

15 July 2026

Johnson & Johnson Q2 2026 results and raises 2026 outlook

Quarterly sales topped $25.3B; adjusted net earnings and EPS rose, free cash flow improved, and full-year revenue guidance was raised above $100B for the first time.
12 June 2026

Roche VENTANA PTEN (SP218) FDA-cleared as PTEN companion diagnostic in prostate cancer

First FDA-cleared IHC companion diagnostic to detect PTEN protein loss and select patients for capivasertib (TRUQAP) plus abiraterone therapy.
30 January 2026

Johnson & Johnson's AKEEGA® Gets CHMP Nod for mHSPC with BRCA1/2 Mutations

CHMP backs AKEEGA® for mHSPC with BRCA1/2 mutations, showing improved progression-free survival and manageable safety profile in Phase 3 AMPLITUDE study.
12 December 2025

FDA Approves Johnson & Johnson's AKEEGA for BRCA2-Mutated Prostate Cancer

FDA approves AKEEGA for BRCA2-mutated prostate cancer, reducing disease progression by 54% and delaying symptoms by 59% in clinical trials.
16 October 2025

Johnson & Johnson's AKEEGA® Gets FDA Priority Review for BRCA-Mutated Prostate Cancer

FDA grants Priority Review to AKEEGA® for BRCA-mutated prostate cancer, showing reduced progression risk and improved outcomes in Phase 3 study.

Who will be producing Abiraterone Acetate in the future?

Find out with chemXplore Alpha

Learn more